Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.42 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.42 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.42 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705567 | 0.91 | ALDH1A1 (0.47) | ALDH1A1LMNAPTGES | |
| SCHEMBL6701422 | 0.91 | HPGD (0.46) | CACNA1GALDH1A1LMNAHSD17B10PTGES | |
| SCHEMBL6704655 | 0.72 | NPC1 (0.49) | TP53MDM2ALDH1A1POLBCNR1 | |
| SCHEMBL5428707 | 0.72 | HPGD (0.48) | CACNA1GALDH1A1LMNAHSD17B10 | |
| SCHEMBL6701163 | 0.69 | LMNA (0.40) | LMNAPOLB | |
| SCHEMBL5226231 | 0.68 | HDAC6 (0.72) | SCN2ASCN10AALDH1A1LMNAPOLB | |
| SCHEMBL6699001 | 0.68 | LMNA (0.46) | ALDH1A1LMNAPOLB | |
| SCHEMBL1926318 | 0.66 | EPHX2 (0.77) | SCN2ASCN10A | |
| SCHEMBL3461078 | 0.65 | HDAC6 (0.70) | SCN2ASCN10AALDH1A1LMNAPOLB | |
| SCHEMBL20764262 | 0.64 | ESRRG (0.78) | TP53MDM2SCN2ASCN10AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102488-A1 | Butenolide and pentenolide derivatives as kinase inhibitors | MORPHOCHEM AG (DE) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102488-A1 | Butenolide and pentenolide derivatives as kinase inhibitors | MAP3K20, MAP3K21, MAP3K1 | TP53 2243/4885MDM2 4040/4885SCN2A 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.